Albert Labs International Corp.
ABRT.CN
Canadian Securities Exchange0.01
CAD
- -
- -
Albert Labs International Corp.
ABRT.CN
(Canadian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Albert Labs International Corp. (CSE: ABRT) operates as a biopharmaceutical drug discovery and development company focused on psychedelic-assisted therapies for mental health conditions with urgent unmet needs; it researches, manufactures and commercializes natural pharmaceutical-quality psilocybin-based medicines, including its lead product KRN-101, a mycelium extract targeted at cancer-related anxiety and distress affecting over 15 million patients worldwide. The company leverages advanced bioreactor technology for scalable, standardized production of active pharmaceutical ingredients meeting Good Laboratory Practice and Good Manufacturing Practice standards; it pursues accelerated regulatory pathways such as Real World Evidence clinical trials in collaboration with partners including the University of Manchester, Christie Hospital and the National Cancer Research Institute in the UK. Albert Labs maintains research and development laboratories in Canada and Portugal, with a clinical focus in the United Kingdom to facilitate global access pathways; founded prior to its 2022 listing on the Canadian Securities Exchange following a reverse takeover and Series A private placement raising CAD$4.7 million, it is headquartered in Burnaby, British Columbia. Recent developments include obtaining a Health Canada licence in 2022 for production, sale via Special Access Programme and export of Schedule 1 substances; filing of US provisional and international PCT patents for proprietary natural psilocybin manufacturing methods; establishment of pre-clinical advisory and clinical advisory boards chaired by experts such as Dr. Ricardo Dinis-Oliveira and Professor Sara Tai; completion of GLP toxicology studies for KRN-101 enabling Clinical Trial Application submissions; and strategic expansions toward parallel UK MHRA and US FDA regulatory approvals alongside a letter of intent with contract research organization NGENū for first-in-human studies, though trading was suspended in 2024 amid a management cessation trade order and CEO resignation. The company serves oncology and mental health markets primarily in North America, Europe and the UK through existing hospital networks and research institutions, positioning KRN-101 for potential licensing, special access programmes and broader mental health applications.